This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Pilot Study Evaluating Nicotine Lozenges and Self Help

This study has been completed.
Oregon Research Institute
Information provided by:
Mayo Clinic Identifier:
First received: April 24, 2009
Last updated: July 14, 2011
Last verified: July 2011
The investigators are hypothesizing that by offering both self-help materials and mailed nicotine lozenges we will be able to help increase tobacco abstinence rates among ST users, as well as decrease tobacco withdrawal.

Condition Intervention Phase
Smokeless Tobacco Use Drug: nicotine replacement therapy Drug: placebo NRT Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Pilot Study to Assess the Effectiveness of the Nicotine Lozenge for Smokeless Tobacco Users

Resource links provided by NLM:

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Number of Participants With Tobacco Abstinence [ Time Frame: 12 weeks ]
    self-reported 7-day point prevalence tobacco abstinence at week 12 (end of treatment)

Enrollment: 60
Study Start Date: April 2008
Study Completion Date: May 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: active
Self-help counseling material and 4 mg nicotine lozenges
Drug: nicotine replacement therapy
4 mg nicotine lozenges, ad lib, for 12 weeks.
Other Name: Nicotine Lozenges
Placebo Comparator: 2
self help counseling material and placebo nicotine lozenges
Drug: placebo NRT
Placebo nicotine lozenges
Other Name: placebo

Detailed Description:
Smokeless tobacco (ST) is a known human carcinogen. Long-term ST use is known to increase the risk for oropharyngeal cancer. Most smokeless tobacco users wish to quit. Assisted-self help interventions (i.e., self-help manual, a targeted video, and two support telephone phone calls) have been shown to be superior to manual-only interventions for increasing tobacco abstinence rates. These interventions lend themselves to widespread dissemination, but abstinence rates at 6 months remains low (21%). Providing nicotine replacement therapy (NRT) to ST users receiving assisted self-help interventions could improve upon these ST abstinence rates. If found to be effective, this intervention may increase the ability to disseminate effective interventions to a population of tobacco users for whom few treatment resources currently exist.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. male;
  2. ≥18 years of age;
  3. report ST as their primary tobacco of use;
  4. have used ST daily for the past 6 months;
  5. indicate that they want to quit;
  6. have been provided with, understand, and have signed the informed consent.

Exclusion Criteria:

  1. previously enrolled in a study involving the use of the nicotine lozenge;
  2. currently using or have completed using (past 30 days) any other behavioral or pharmacologic tobacco treatment program;
  3. currently enrolled in another research study;
  4. describe having a medical history of: a) unstable angina; b) myocardial infarction within the past 6 months; c) cardiac dysrhythmia other than medication-controlled atrial fibrillation or PSVT; or d) medically-treated or untreated hypertension with BP ≥ 180 systolic OR ≥ 100 diastolic;
  5. have phenylketonuria (PKU) [nicotine lozenges contain aspartame which is metabolized to phenylalanine and not processed in individuals with PKU];
  6. have another member of their household already participating in this study;
  7. have other medical or psychiatric conditions that would exclude the participant;
  8. have a score of ≥ 15 on the Patient Health Questionnaire (PHQ-9) on the phone call pre-screen.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00888459

United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, Oregon
Oregon Research Institute
Eugene, Oregon, United States, 97403
Sponsors and Collaborators
Mayo Clinic
Oregon Research Institute
Principal Investigator: Jon O Ebbert, MD Mayo Clinic
  More Information

Responsible Party: Jon Ebbert, MD, Mayo Clinic Identifier: NCT00888459     History of Changes
Other Study ID Numbers: 07-008574
Study First Received: April 24, 2009
Results First Received: October 4, 2010
Last Updated: July 14, 2011

Keywords provided by Mayo Clinic:
nicotine lozenges

Additional relevant MeSH terms:
Ganglionic Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on August 22, 2017